FindTrial
Sign In

the Study of Ischemic White Matter injury of Moyamoya Diseases

Wnt5a regulates choronic ischemic white matter injury of Moyamoya Diseases

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300072890
Enrollment
Unknown
Registered
2023-06-27
Start date
2023-07-01
Completion date
Unknown
Last updated
2023-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moyamoya disease

Interventions

surgical group, non-surgical group, normal control group:Whether to surgery

Sponsors

Nanjing Medical University Affiliated Brain Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) All patients are diagnosed as moyamoya disease by DSA according to the "Interpretation of the Treatment Guidelines (Japan) in 2012"; (2) All patients and family members accept surgery according to their own wishes and actual condition, and sign the informed consent. (3)presence of hemodynamic compromise; (4) no contraindication of MRI; (5) older than 18 years.

Exclusion criteria

Exclusion criteria: (1) Poor quality of DSA and magnetic resonance images; (2) Known contraindication to MRI; (3) Prior bypass surgery; (4) History of Moyamoya syndrome, immune system disease, Down syndrome, or sickle cell disorder, etc.

Design outcomes

Primary

MeasureTime frame
Cognitive functional score;MR-DTI;Brain perfusion;—

Countries

China

Contacts

Public ContactJinbing Zhao

Nanjing Medical University Affiliated Brain Hospital

zhaojb@njmu.edu.cn+86 180 0515 1226

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026